Novo Nordisk’s two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for serious breaches of the ABPI Code of Practice has come to an end [1]. Novo Nordisk’s return to ...

Investing.com -- After a two-year suspension due to serious breaches of the Association of the British Pharmaceutical (TADAWUL:2070) Industry (ABPI) Code of Practice, Novo Nordisk (NYSE ...

On Monday, Novo Nordisk A/S (NYSE:NVO) returned to full membership of the Association of the British Pharmaceutical Industry (ABPI) following extensive audits of the Wegovy maker's compliance ...

Novo Nordisk regained full ABPI membership after audits confirmed compliance with governance and promotional standards. The company was suspended in 2023 over a complaint alleging inducements to ...

Investing.com -- After a two-year suspension due to serious breaches of the Association of the British Pharmaceutical (TADAWUL:2070) Industry (ABPI) Code of Practice, Novo Nordisk (NYSE:NVO) has been ...